Dean Destructo
New member
[h=2][/h][FONT="]Millions of individuals have used illicit anabolic-androgenic steroids (AAS), but the long-term cardiovascular associations of these drugs remains incompletely understood.
Employing a cross-sectional cohort design, we recruited 140 experienced male weightlifters aged 34–54 years, comprising 86 men reporting at least 2 years of cumulative lifetime AAS use and 54 non-using men. Using transthoracic echocardiography and coronary computed tomography angiography, we assessed 3 primary outcome measures: left ventricular (LV) systolic function (left ventricular ejection fraction [LVEF]), LV diastolic function (early relaxation velocity [E´]), and coronary atherosclerosis (coronary artery plaque volume).
Compared to non-users, AAS users demonstrated relatively reduced LV systolic function (mean±SD LVEF = 52±11% vs. 63±8%; P<0.001) and diastolic function (E´ = 9.3±2.4 cm/s vs. 11.1±2.0 cm/s; P<0.001). Users currently taking AAS at the time of evaluation (N = 58) showed significantly reduced LV systolic (LVEF = 49±10% vs. 58±10%; P<0.001) and diastolic function (E´ = 8.9±2.4 cm/s vs. 10.1±2.4 cm/s; P=0.035) compared to users currently off-drug (N = 28). Additionally, AAS users demonstrated higher coronary artery plaque volume then nonusers (median [interquartile range] 3 [0, 174] mL3 vs. 0 [0, 69] mL3, P = 0.012). Lifetime AAS dose was strongly associated with coronary atherosclerotic burden (increase [95% confidence interval] in rank of plaque volume for each 10-year increase in cumulative duration of AAS use: 0.60 SD units [0.16 to 1.03 SD units]; P = 0.008).
[/FONT]
[FONT="][h=2]Conclusions[/h]Long-term AAS use appears to be associated with myocardial dysfunction and accelerated coronary atherosclerosis. These forms of AAS-associated adverse cardiovascular phenotypes may represent a previously under-recognized public-health problem.
[/FONT]
[FONT="]Keywords: Anabolic-androgenic steroids, cardiology, diastolic dysfunction, cardiomyopathy, atherosclerosis, men
[/FONT]
Employing a cross-sectional cohort design, we recruited 140 experienced male weightlifters aged 34–54 years, comprising 86 men reporting at least 2 years of cumulative lifetime AAS use and 54 non-using men. Using transthoracic echocardiography and coronary computed tomography angiography, we assessed 3 primary outcome measures: left ventricular (LV) systolic function (left ventricular ejection fraction [LVEF]), LV diastolic function (early relaxation velocity [E´]), and coronary atherosclerosis (coronary artery plaque volume).
Compared to non-users, AAS users demonstrated relatively reduced LV systolic function (mean±SD LVEF = 52±11% vs. 63±8%; P<0.001) and diastolic function (E´ = 9.3±2.4 cm/s vs. 11.1±2.0 cm/s; P<0.001). Users currently taking AAS at the time of evaluation (N = 58) showed significantly reduced LV systolic (LVEF = 49±10% vs. 58±10%; P<0.001) and diastolic function (E´ = 8.9±2.4 cm/s vs. 10.1±2.4 cm/s; P=0.035) compared to users currently off-drug (N = 28). Additionally, AAS users demonstrated higher coronary artery plaque volume then nonusers (median [interquartile range] 3 [0, 174] mL3 vs. 0 [0, 69] mL3, P = 0.012). Lifetime AAS dose was strongly associated with coronary atherosclerotic burden (increase [95% confidence interval] in rank of plaque volume for each 10-year increase in cumulative duration of AAS use: 0.60 SD units [0.16 to 1.03 SD units]; P = 0.008).
[/FONT]
[FONT="][h=2]Conclusions[/h]Long-term AAS use appears to be associated with myocardial dysfunction and accelerated coronary atherosclerosis. These forms of AAS-associated adverse cardiovascular phenotypes may represent a previously under-recognized public-health problem.
[/FONT]
[FONT="]Keywords: Anabolic-androgenic steroids, cardiology, diastolic dysfunction, cardiomyopathy, atherosclerosis, men
[/FONT]
